Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

NCT06567743 is registered in ClinicalTrials.gov with CG Oncology, Inc. as lead sponsor.

NCT NCT06567743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06567743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Lead sponsor
CG Oncology, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2024
Completion date
December 30, 2027
Enrollment
325 (estimated)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk non-muscle-invasive bladder cancer